TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -166.23 Million TWD | 35.87% |
| 2022 | -259.19 Million TWD | 44.08% |
| 2021 | -463.48 Million TWD | -158.62% |
| 2020 | -179.21 Million TWD | 69.01% |
| 2019 | -578.29 Million TWD | -80.28% |
| 2018 | -320.78 Million TWD | 41.16% |
| 2017 | -545.21 Million TWD | -74.25% |
| 2016 | -312.89 Million TWD | 33.66% |
| 2015 | -471.68 Million TWD | -68.81% |
| 2014 | -279.4 Million TWD | -11.02% |
| 2013 | -251.67 Million TWD | -2.99% |
| 2012 | -244.36 Million TWD | -1.49% |
| 2011 | -240.77 Million TWD | 14.79% |
| 2010 | -282.57 Million TWD | -27.78% |
| 2009 | -221.14 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -37.05 Million TWD | -39.82% |
| 2024 Q2 | -41.25 Million TWD | -11.34% |
| 2023 Q2 | -44.09 Million TWD | 42.94% |
| 2023 FY | -166.23 Million TWD | 35.87% |
| 2023 Q1 | -77.27 Million TWD | -123.56% |
| 2023 Q4 | -26.49 Million TWD | -1159.46% |
| 2023 Q3 | -2.1 Million TWD | 95.23% |
| 2022 Q2 | -73.33 Million TWD | 37.86% |
| 2022 Q1 | -118.02 Million TWD | 60.25% |
| 2022 FY | -259.19 Million TWD | 44.08% |
| 2022 Q4 | -34.56 Million TWD | -3.92% |
| 2022 Q3 | -33.26 Million TWD | 54.65% |
| 2021 Q4 | -296.96 Million TWD | -333.87% |
| 2021 FY | -463.48 Million TWD | -158.62% |
| 2021 Q1 | -85.85 Million TWD | 26.46% |
| 2021 Q2 | -89.82 Million TWD | -4.62% |
| 2021 Q3 | -68.44 Million TWD | 23.8% |
| 2020 Q1 | 43.57 Million TWD | 6652.18% |
| 2020 FY | -179.21 Million TWD | 69.01% |
| 2020 Q2 | -2.09 Million TWD | -104.82% |
| 2020 Q3 | -57.49 Million TWD | -2640.28% |
| 2020 Q4 | -116.74 Million TWD | -103.06% |
| 2019 Q4 | -665 Thousand TWD | 99.73% |
| 2019 Q1 | -65.79 Million TWD | 45.41% |
| 2019 Q2 | -74.59 Million TWD | -13.38% |
| 2019 FY | -578.29 Million TWD | -80.28% |
| 2019 Q3 | -248.94 Million TWD | -233.74% |
| 2018 Q2 | -136.72 Million TWD | -255.84% |
| 2018 Q4 | -120.52 Million TWD | 20.32% |
| 2018 Q3 | -151.26 Million TWD | -10.64% |
| 2018 Q1 | 87.73 Million TWD | 149.68% |
| 2018 FY | -320.78 Million TWD | 41.16% |
| 2017 Q2 | -192.64 Million TWD | -174.04% |
| 2017 FY | -545.21 Million TWD | -74.25% |
| 2017 Q4 | -176.6 Million TWD | -67.13% |
| 2017 Q1 | -70.3 Million TWD | 38.88% |
| 2017 Q3 | -105.66 Million TWD | 45.15% |
| 2016 FY | -312.89 Million TWD | 33.66% |
| 2016 Q4 | -115.02 Million TWD | -105.72% |
| 2016 Q3 | -55.91 Million TWD | 28.33% |
| 2016 Q2 | -78.02 Million TWD | -22.03% |
| 2016 Q1 | -63.93 Million TWD | 35.11% |
| 2015 Q1 | -65.49 Million TWD | 8.96% |
| 2015 FY | -471.68 Million TWD | -68.81% |
| 2015 Q4 | -98.52 Million TWD | 47.75% |
| 2015 Q3 | -188.55 Million TWD | -58.31% |
| 2015 Q2 | -119.1 Million TWD | -81.84% |
| 2014 Q2 | -54.71 Million TWD | 22.56% |
| 2014 FY | -279.4 Million TWD | -11.02% |
| 2014 Q1 | -70.65 Million TWD | 17.39% |
| 2014 Q3 | -82.09 Million TWD | -50.03% |
| 2014 Q4 | -71.94 Million TWD | 12.36% |
| 2013 Q1 | -43.19 Million TWD | 25.63% |
| 2013 Q2 | -43.19 Million TWD | 0.0% |
| 2013 Q3 | -85.53 Million TWD | -98.01% |
| 2013 FY | -251.67 Million TWD | -2.99% |
| 2013 Q4 | -85.53 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 FY | -244.36 Million TWD | -1.49% |
| 2012 Q3 | -58.08 Million TWD | 0.0% |
| 2012 Q4 | -58.08 Million TWD | 0.0% |
| 2011 FY | -240.77 Million TWD | 14.79% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -282.57 Million TWD | -27.78% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | -221.14 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bio Preventive Medicine Corp. | -70.58 Million TWD | -135.515% |
| Genomics BioSci & Tech. Co.,Ltd. | -84.99 Million TWD | -95.58% |
| Advagene Biopharma Co., Ltd. | -93.33 Million TWD | -78.1% |
| Taiwan Bio Therapeutics Co., Ltd | -212.2 Million TWD | 21.665% |
| NaviFUS Corp. | -76.42 Million TWD | -117.506% |
| G&E Herbal Biotechnology Co., Ltd. | 80.68 Million TWD | 306.027% |
| TaiRx, Inc. | -214.69 Million TWD | 22.573% |
| Sinew Pharma Inc. | -186.25 Million TWD | 10.75% |
| Lin BioScience, Inc. | -1.09 Billion TWD | 84.844% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.61 Million TWD | -2414.841% |
| Lumosa Therapeutics Co., Ltd. | -375.62 Million TWD | 55.745% |
| Anti-Microbial Savior BioteQ Co., Ltd | -56.74 Million TWD | -192.923% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 281.85 Million TWD | 158.978% |
| AP Biosciences Inc | -347.47 Million TWD | 52.161% |
| Sunmax Biotechnology Co., Ltd. | 894.79 Million TWD | 118.578% |
| RBC Bioscience Corporation | 14.53 Million TWD | 1243.345% |
| Syngen Biotech Co.,Ltd. | 334.08 Million TWD | 149.758% |
| EirGenix Inc. | -1.03 Billion TWD | 83.892% |
| Enimmune corporation | -243.47 Million TWD | 31.726% |
| Lukas Biomedical Inc. | -43.56 Million TWD | -281.614% |
| BRIM Biotechnology, Inc. | -694.12 Million TWD | 76.052% |
| 3D Global Biotech Inc. | -62.85 Million TWD | -164.476% |
| Mycenax Biotech Inc. | -602.1 Million TWD | 72.392% |
| TCI GENE Inc. | 10.04 Million TWD | 1754.204% |
| SynCore Biotechnology Co.,Ltd | -45.5 Million TWD | -265.327% |
| Oneness Biotech Co., Ltd. | -1.09 Billion TWD | 84.842% |
| Eusol Biotech Co.,Ltd. | -41.48 Million TWD | -300.73% |
| Feng Chi Biotech Corp. | 24.16 Million TWD | 787.985% |
| NeoCore Technology Co., Ltd. | -84.94 Million TWD | -95.695% |
| TWi Biotechnology, Inc. | -169.55 Million TWD | 1.961% |
| Neith Corporation | -48.85 Million TWD | -240.261% |
| Sunny Pharmtech Inc. | -72.09 Million TWD | -130.569% |
| VBI | -16.13 Million TWD | -930.443% |
| Ever Supreme Bio Technology Co., Ltd | 337.73 Million TWD | 149.22% |
| GeneReach Biotechnology Corp. | -229.28 Million TWD | 27.5% |
| Shine-On BioMedical Co.,Ltd. | -62.68 Million TWD | -165.193% |
| CHO Pharma, Inc. | -268.99 Million TWD | 38.204% |
| Andros Pharmaceuticals Co.,Ltd | -67.69 Million TWD | -145.552% |
| MegaPro Biomedical Co., Ltd | -127.25 Million TWD | -30.626% |
| Visgeneer Inc. | -21.15 Million TWD | -685.628% |
| Greenyn Biotechnology Co., Ltd | 159.81 Million TWD | 204.013% |
| BioLASCO Taiwan Co., Ltd. | 63.33 Million TWD | 362.463% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -93.95 Million TWD | -76.926% |
| Sagittarius Life Science Corp | -64.37 Million TWD | -158.219% |
| BioGend Therapeutics Co., Ltd. | -176.54 Million TWD | 5.84% |
| GlycoNex Incorporation | -259.86 Million TWD | 36.032% |
| Medigen Biotechnology Corp. | -1.23 Billion TWD | 86.519% |
| Pharmosa Biopharm Inc. | -2.82 Million TWD | -5786.367% |
| PharmaEngine, Inc. | 277.18 Million TWD | 159.972% |
| Intech Biopharm Corporation | -304.39 Million TWD | 45.39% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -2.25 Million TWD | -7278.207% |
| BiOptic Inc. | 44.05 Million TWD | 477.343% |
| TaiGen Biopharmaceuticals Holdings Limited | -174.69 Million TWD | 4.847% |
| Senhwa Biosciences, Inc. | -311.11 Million TWD | 46.569% |
| NatureWise Biotech & Medicals Corporation | 3.43 Million TWD | 4940.74% |
| OBI Pharma, Inc. | -2.08 Billion TWD | 92.046% |
| Savior Lifetec Corporation | -2.42 Million TWD | -6769.05% |
| Great Novel Therapeutics Biotech & Medicals | -65.81 Million TWD | -152.554% |
| Level Biotechnology Inc. | 67.55 Million TWD | 346.079% |
| Medigen Vaccine Biologics Corporation | -1.21 Billion TWD | 86.305% |
| Meribank Biotech Co., Ltd | -123.15 Million TWD | -34.978% |
| Acepodia, Inc. | -435.97 Million TWD | 61.871% |
| Caliway Biopharmaceuticals Co., Ltd. | -487.95 Million TWD | 65.933% |